Possible risk factors associated with greater damage in systemic lupus erythematosus patients: an Egyptian multicenter study

Abstract

Objectives

Systemic lupus erythematosus (SLE) is a prototypic multisystem autoimmune disorder. The total damage in a patient with SLE may result from SLE itself or from any other pathologic process. The aim of this study was to assess risk factors of greater damage in a sample of Egyptian SLE patients.

Methods

This Egyptian multicenter retrospective study included 100 SLE patients: 64 patients from Cairo University Hospitals and 36 patients from Zagazig University Hospitals. The Systemic Lupus International Collaborative Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (ACR-DI) was used to document the damage in each patient.

Results

The total SLICC/ACR-DI score ranged from 0 to 8. A higher DI score was found in hypertensive patients, compared to normotensive patients; and among those with positive anti-phospholipid antibodies, compared to those with negative anti-phospholipid antibodies. This difference was statistically significant (p < 0.01). Also, a higher DI score was found in cyclophosphamide users, compared to non-users; and in those with proteinuria and seizures, compared to those without; and the difference was statistically significant (p < 0.05). There was a significant positive correlation between the DI and patient age (p < 0.05).

Conclusions

Damage in SLE cannot be prevented completely, as SLE disease is considered an aggressive disease treated by aggressive medications, but rheumatologists should try to minimize damage as much as possible to maintain the patients’ health, functioning and general wellbeing.

Keywords

Age blood pressure damage index Egypt lupus proteinuria risk factors seizures systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Bertsias

Cervera

Boumpas

. Systemic lupus erythematosus: Pathogenesis and clinical features. EULAR textbook of rheumatology, Geneva: European League Against Rheumatism (EULAR), 2012, pp. 476–505.

Bethunaickan

Berthier

Ramanujam

. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 2011; 186: 4994–5003.

Hopkins

Belmont

Buyon

. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632–641.

Gladman

Urowitz

Goldsmith

. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage. Arthritis Rheum 1997; 40: 809–813.

Gladman

Ginzler

Goldsmith

Fortin

Liang

Urowitz

. Systemic Lupus International Collaborative Clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992; 19: 1820–1821.

Zonana-Nacach

Camargo-Coronel

Yanez

. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: Relationship with disease duration. Lupus 1998; 7: 119–123.

Sutcliffe

Clarke

Gordon

Farewell

Isenberg

. The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology 1999; 38: 1130–1137.

Nossent

. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: Changes in and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 1998; 25: 654–659.

Mok

Lee

Lau

Wong

. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000; 39: 399–406.

10.

Yee

Hussein

Skan

Bowman

Situnayake

Gordon

. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276–279.

11.

Nossent

12.

Stoll

Seifert

Isenberg

. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254.

13.

Mikdashi

Handwerger

. Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the Maryland Lupus Cohort. Rheumatology 2004; 43: 1555–1560.

14.

Carvalho

Marinho

Leal

. Association between vitamin D receptor (VDR) gene polymorphisms and systemic lupus erythematosus in Portuguese patients. Lupus 2015; 24: 846–853.

15.

Gladman

Ginzler

Goldsmith

. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheumatism 1996; 39: 363–369.

16.

Maddison

Farewell

Isenberg

. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 2002; 29: 913–917.

17.

Becker-Merok

Nossent

. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006; 33: 1570–1577.

18.

Stoll

Sutcliffe

Mach

. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: A 5-yr prospective study. Rheumatology 2004; 43: 1039–1044.

19.

Mok

Cheung

. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: A 2-year prospective study. Scand J Rheumatol 2009; 38: 121–127.

20.

Petri

Bello

Fang

Magder

. Vitamin D in systemic lupus erythematosus: Modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheumatol 2013; 65: 1865–1871.

21.

Parks

De Roos

. Pesticides, chemical and industrial exposures in relation to systemic lupus erythematosus. Lupus 2014; 23: 527–536.

22.

Yanbaeva

Dentener

Creutzberg

. Systemic effects of smoking. Chest 2007; 131: 1557–1566.

23.

Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2014, www.ncbi.nlm.nih.gov/pubmed/24834926.

24.

Peeva

Zouali

. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005; 101: 123–143.

25.

Buyon

Petri

Kim

. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142: 953–962.

26.

Walker

. Estrogen and autoimmune disease. Clin Rev Allergy Immunol 2011; 40: 60–65.

27.

Prasad

Ibanez

Gladman

. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 2006; 15: 285–291.

28.

Fessler

Alarcon

McGwin

. Systemic lupus erythematosus in three ethnic groups: Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473–1480.

29.

Gladman

Ibanez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

30.

American College of Rheumatology. Development of classification and response criteria for rheumatic diseases. Arthritis Care Res 2006; 55: 348–352.

31.

Petri

Orbai

Magder

. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

32.

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295–306.

33.

Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885–889.

34.

Karlson

Daltroy

Lew

. The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 47–56.

35.

Cooper

Treadwell

St Clair

Gilkeson

Dooley

. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 993–999.

36.

Soares

Reis

Papi

JAS

Cardoso

CRL

. Rate, pattern and factors related do damage in Brazilian systemic lupus erythematosus patients. Lupus 2003; 12: 788–794.

37.

Toro

Capote

Hechavarría

Paneque

Kokuina

. Damage in Cuban patients with systemic lupus erythematosus. Relation with disease features. M Reumatol Clin 2010; 6: 11–15.

38.

Petri

Purvey

Fang

Magder

. Predictors of organ damage in systemic lupus erythematosus: The Hopkins’ Lupus Cohort. Arthritis Rheum 2012; 64: 4021–4028.

39.

Alarcon

McGwin

Bartolucci

. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797–2806.

40.

Alarcon

Roseman

McGwin

. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004; 43: 202–205.

41.

Hanly

. The neuropsychiatric SLE SLICC inception cohort study. Lupus 2008; 17: 1059–1063.

42.

Rabbani

Habib

Islam

. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009; 18: 848–855.

43.

Amigo

Goycochea-Robles

Espinosa-Cuervo

. Development and initial validation of a damage index (DIaPS) in patients with thrombotic antiphospholipid syndrome. Lupus 2015; 24: 927–934.

44.

Ruiz-Irastorza

Egurbide

Martinez-Berriotxoa

. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004; 13: 900–905.